Cefuroxime

Caitlin Soto, PharmD, BCIDP , Edina Avdic, Pharm.D.

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Uncomplicated urinary tract infections caused by E. coli or K. pneumoniae (PO and IV)
  • Uncomplicated skin and skin-structure infections caused by S. aureus or S. pyogenes (PO and IV) E. coli, Klebsiella spp., and Enterobacter spp. (IV)
    • Impetigo (pediatric patients) (PO)
  • Upper respiratory tract infections including acute otitis media, acute maxillary sinusitis, acute exacerbation of chronic bronchitis, and pharyngitis/tonsillitis (PO)
  • Early Lyme disease (erythema migrans) caused by B. burgdorferi (PO)
  • Lower respiratory tract infections including community-acquired pneumonia (CAP, IV)
  • Septicemia caused by S. aureus, S. pneumoniae, E. coli, H. influenzae, Klebsiella spp. (IV only)
  • Meningitis S. pneumoniae, H. influenzae, N. meningitidis, and S. aureus (MSSA) (IV only).
    • Author’s comment: Nafcillin preferred for MSSA meningitis.
  • Bone and joint infections caused by MSSA (IV)
  • Uncomplicated urethral and endocervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended, oral and IV)

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Late Lyme arthritis
  • CAP (oral cefuroxime)

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.